39 clinical trials matched your search for Prostate Cancer. You can click one of the clinical trials below for more information, or click the Search Again button to enter different search text.

Search Again
Condition Study Title Investigator
Prostate Cancer IRONMAN: International Registry for Men with Advanced Prostate Cancer Mark Stein, MD
Prostate Cancer Study of androgen deprivation therapy followed by chemoimmunotherpy for newly metastatic hormone-sensitive prostate cancer (mHSPC) Mark Stein, MD
Prostate Cancer Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer Mark Stein, MD
Prostate Cancer Study of BMS-986218 + Degarelix Acetate vs. Degarelix Acetate Alone in Men with Prostate Cancer Karie D. Runcie, MD
Prostate Cancer Study of Abiraterone Acetate, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer Mark Stein, MD
Prostate Cancer PLX2853 with Abiraterone Acetate, Prednisone, and Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Mark Stein, MD
Prostate Cancer Study of ADXS-504 in Patients with Prostate Cancer Mark Stein, MD
Prostate Cancer Study of JNJ-75229414 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Mark Stein, MD
Prostate Cancer Study of BMS-986218 Alone or in Combination with Nivolumab for Male Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Karie D. Runcie, MD
Prostate Cancer Study of XmAb20717 Alone or in Combination with Chemotherapy in Patients with Prostate Cancer Mark Stein, MD
Prostate Cancer Study of Cabozantinib in Patients with Prostate Cancer who Previously Received Anti-Androgen Therapy Mark Stein, MD
Cancer Molecular Analysis for Therapy Choice (MATCH) Richard Carvajal, MD
Cancer Early Onset Malignancies Initiative (EOMI) Matthew Ingham, MD
Cancer Study of Drug (MK-2118) in Patients with Solid Tumors or Lymphomas Matthew Ingham, MD
Cancer Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Mark Stein, MD
Cancer Study of BA3011 in Subjects with Advanced Solid Tumors Matthew Ingham, MD
Cancer Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) Brian Henick, MD
Cancer A Study in Subjects With Advanced Cancer Richard Carvajal, MD
Cancer TCR-engineered T Cells in Solid Tumors (ACTengine) Ran Reshef, MD
Cancer Smartphone App for Cancer Medication Adherence Melissa Accordino, MD
Cancer Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors Richard Carvajal, MD
Cancer Study of RTX-240 in Adults with Relapsed/Refractory or Locally Advanced Solid Tumors Mark Stein, MD
Cancer Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer Bret Taback, MD
Cancer A Study of ASP9801 in Patients With Advanced Metastatic Solid Tumors Matthew Ingham, MD
Cancer COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors Benjamin Izar, MD
Cancer A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Cancer Benjamin Izar, MD
Cancer Study of IV Contrast on Patients Going Through Image Guided Radiation Therapy (IGRT) for Abdominal and Pelvic Cancer David Horowitz, MD
Cancer Study of New Oral Anti-Cancer Drug (OACD) Dawn Hershman, MD
Cancer First-in-Human Study of DS-7300a in Subjects with Advanced Cancer Mark Stein, MD
Cancer Study of MPT-0118 Alone or in Combination with Keytruda in Patients with Advanced or Metastatic Cancer Shaheer Khan, DO
Cancer Study of Financial Navigator Addressing Cancer-Related Financial Hardship in Cancer Patients and Their Spouses Dawn Hershman, MD
Cancer Study of INCB106385 Alone or in Combination with INCMGA00012 in Patients with Advanced Cancer Mark Stein, MD
Cancer Study of RP-3500 in Combination with PARP Inhibitor for Patients with Advanced Cancer Benjamin Herzberg, MD
Cancer Study of Ulixertinib (BVD-523) for Patients with Advanced Cancer that Show Genetic Alterations Richard Carvajal, MD
Cancer Study of PF-07263689 Alone or in Combination with Sasanlimab for Patients with Advanced Cancer Brian Henick, MD
Cancer Study of IDE397 in Patients with Advanced Solid Tumors Benjamin Herzberg, MD
Cancer Study of RP-6306 in Combination with Gemcitabine (Chemotherapy) for Patients with Advanced Solid Tumors Ryan Moy, MD
Cancer Study of CS5001 in Patients with Advanced Solid Tumors Richard Carvajal, MD
Cancer Study of ASP3082 in Patients with Advanced Cancer with a KRAS G12D Mutation Benjamin Herzberg, MD